Search
for

    GlossarySteroid 5 Alpha-Reductase 1 (Type I 5α-reductase)

    converts testosterone into a more potent androgen, dihydrotestosterone

    Steroid 5 Alpha-Reductase 1 (SRD5A1) is an enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen hormone. This enzyme plays a significant role in the development of male characteristics and is also implicated in conditions like androgenic alopecia (male pattern baldness) and benign prostatic hyperplasia.

    Related Terms

    Products matching "type i 5α-reductase"

    Tracking 4 products like 132 URODART 0.5MG 28 capsule, 157 Finast (Finasteride 5mg), 158 Fincar 5mg and 161 Finax from by companies like Minoxidil Express and Inhouse Pharmacy. View all 4 products »

    Learn

    4 / 4 results

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Metformin

      diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community 5ARI (dutasteride) Associated with Adverse Metabolic Effects

       23 upvotes   6 years ago
      Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

      community FCE 28260: A Forgotten 5α-Reductase Inhibition

        4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.